Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday after BMO Capital Markets raised their price target on the stock from $50.00 to $70.00. BMO Capital Markets currently has an outperform rating on the stock. 4D Molecular Therapeutics traded as high as $30.40 and […]
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...
Privium Fund Management B.V. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund purchased 33,680 shares of the company’s stock, valued at approximately $429,000. Other hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC […]
Privium Fund Management B.V. acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 33,680 shares of the company’s stock, valued at approximately $429,000. Privium Fund Management B.V. owned 0.08% of 4D […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […]